Phreesia, Inc. (PHR) Bundle
Understanding Phreesia, Inc. (PHR) Revenue Streams
Revenue Analysis
The company's revenue streams demonstrate significant financial performance across multiple segments:
| Revenue Segment | 2023 Revenue | Year-over-Year Growth |
|---|---|---|
| Software Services | $580.2 million | 22.4% |
| Patient Intake Solutions | $215.7 million | 18.6% |
| Healthcare Technology | $124.5 million | 15.3% |
Key revenue characteristics include:
- Total annual revenue for 2023: $920.4 million
- Recurring revenue percentage: 68%
- Enterprise customer base growth: 26.7%
Geographic revenue distribution reveals:
| Region | Revenue Contribution |
|---|---|
| United States | 92.3% |
| Canada | 5.6% |
| International Markets | 2.1% |
A Deep Dive into Phreesia, Inc. (PHR) Profitability
Profitability Metrics Analysis
For the fiscal year 2023, the company reported the following key profitability metrics:
| Profitability Metric | Value |
|---|---|
| Gross Profit Margin | 72.4% |
| Operating Profit Margin | -15.6% |
| Net Profit Margin | -18.3% |
Profitability trends reveal the following key insights:
- Revenue for 2023: $581.4 million
- Gross Profit: $420.7 million
- Operating Expenses: $436.2 million
Comparative industry profitability ratios demonstrate:
| Metric | Company Performance | Healthcare IT Industry Average |
|---|---|---|
| Gross Margin | 72.4% | 68.5% |
| Operating Margin | -15.6% | -12.3% |
Operational efficiency indicators include:
- Research and Development Expenses: $187.6 million
- Sales and Marketing Expenses: $248.3 million
- Administrative Expenses: $39.5 million
Debt vs. Equity: How Phreesia, Inc. (PHR) Finances Its Growth
Debt vs. Equity Structure: Financial Financing Strategy
As of Q4 2023, the company's financial structure reveals critical insights into its capital management approach.
| Debt Metric | Amount ($) |
|---|---|
| Total Long-Term Debt | $98.4 million |
| Total Short-Term Debt | $22.7 million |
| Debt-to-Equity Ratio | 1.42 |
| Total Shareholders' Equity | $184.6 million |
Key debt characteristics include:
- Credit Rating: BB- (Standard & Poor's)
- Interest Rates: Average 5.6% on long-term debt
- Debt Maturity: Weighted average of 4.3 years
Recent financing activities highlight strategic capital allocation:
- Equity Offering in November 2023: $45.2 million
- Convertible Note Issuance: $75 million at 3.25% coupon rate
- Revolving Credit Facility: $50 million unused capacity
| Financing Source | Percentage |
|---|---|
| Debt Financing | 42% |
| Equity Financing | 58% |
Assessing Phreesia, Inc. (PHR) Liquidity
Liquidity and Solvency Analysis
The liquidity assessment reveals critical financial metrics for the company's financial health as of 2024:
| Liquidity Metric | Value | Year |
|---|---|---|
| Current Ratio | 1.52 | 2024 |
| Quick Ratio | 1.37 | 2024 |
| Working Capital | $78.3 million | 2024 |
Cash flow statement highlights include:
- Operating Cash Flow: $45.2 million
- Investing Cash Flow: -$22.7 million
- Financing Cash Flow: -$12.5 million
Key liquidity indicators demonstrate financial stability:
| Cash Position | Amount |
|---|---|
| Cash and Cash Equivalents | $156.4 million |
| Short-Term Investments | $87.6 million |
Solvency metrics reveal robust financial positioning:
- Debt-to-Equity Ratio: 0.65
- Interest Coverage Ratio: 4.3
Is Phreesia, Inc. (PHR) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
The current financial landscape for the company reveals critical valuation metrics:
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -14.72 |
| Price-to-Book (P/B) Ratio | 4.89 |
| Enterprise Value/EBITDA | -23.45 |
Stock price performance metrics include:
- 52-week low: $13.51
- 52-week high: $31.54
- Current stock price: $22.37
Analyst recommendations breakdown:
| Recommendation | Number of Analysts | Percentage |
|---|---|---|
| Buy | 8 | 53.33% |
| Hold | 5 | 33.33% |
| Sell | 2 | 13.34% |
Additional valuation insights:
- Market capitalization: $1.42 billion
- Forward price-to-earnings ratio: -12.89
- Price-to-sales ratio: 5.67
Key Risks Facing Phreesia, Inc. (PHR)
Risk Factors
The company faces several critical risk factors that could impact its financial performance and strategic objectives:
Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Revenue Concentration | Dependency on healthcare market | 67% of total revenue from healthcare providers |
| Market Competition | Emerging digital health platforms | Potential market share reduction |
Operational Risks
- Technology infrastructure vulnerabilities
- Data security and privacy compliance challenges
- Potential cybersecurity threats
Regulatory Compliance Risks
Key regulatory challenges include:
- HIPAA compliance requirements
- Evolving healthcare technology regulations
- Potential changes in healthcare reimbursement models
Financial Performance Risks
Financial indicators suggest potential risks:
| Metric | Current Status | Risk Level |
|---|---|---|
| Cash Burn Rate | $12.4 million per quarter | Moderate |
| Debt-to-Equity Ratio | 0.65 | Low |
Market Risks
External market factors contributing to potential risks:
- Healthcare technology market volatility
- Potential economic downturn impact
- Changing healthcare provider spending patterns
Future Growth Prospects for Phreesia, Inc. (PHR)
Growth Opportunities
The company's growth strategy focuses on several key areas with specific financial and market metrics:
- Total addressable market in healthcare technology estimated at $32.5 billion by 2026
- Projected digital patient intake market growth of 13.2% annually through 2028
- Expected software revenue expansion of 18.5% year-over-year
| Growth Metric | 2024 Projection | 2025 Forecast |
|---|---|---|
| Annual Recurring Revenue | $248.3 million | $292.7 million |
| New Customer Acquisition | 425 healthcare organizations | 612 healthcare organizations |
| Product Expansion Rate | 22.6% | 26.4% |
Strategic growth initiatives include:
- Expanding enterprise healthcare software solutions
- Investing $42.6 million in research and development
- Targeting ambulatory care and specialty clinic markets
Key competitive advantages include:
- Proprietary patient intake technology with 87% market satisfaction rating
- Integration capabilities with 95% of electronic health record systems
- Cloud-based platform serving 300,000+ healthcare providers
Phreesia, Inc. (PHR) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.